Cookies on this site

Listen to TWiM reveal how we collected thousands of Mycobaterium tuberculosis samples from patients worldwide with each sample being sequenced so we knew its entire genome and also being tested for susceptibility to 13 different antibiotics. This project, called CRyPTIC, allowed us and other researchers to map out many of the genetic mutations that confer antibiotic resistance in tuberculosis, which is a difficult disease to treat.

This episode features the CRyPTIC project, and the amazing work of Zooniverse volunteers that resulted in our MMM PPIEP Bash the Bug website, amongst other relevant projects.

Click here to listen to the podcast on This Week in Microbiology website.

Similar stories

Immune response may be harnessed to control HIV

Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.

Oxford and GSK launch £50m programme to advance cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Fitness compensation in m.tuberculosis: a game of genetic chess

Viktoria Brunner takes us behind the scenes of their latest publication 'Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis' published in Microbial Genomics.

Emerging Leaders Prize recognises future leaders in hepatitis research

Three outstanding hepatitis researchers have been announced today as winners of the Medical Research Foundation’s seventh Emerging Leaders Prize.

A global collaboration to develop next-generation COVID-19 and flu vaccines

Today Oxford University has launched a new global collaboration backed by £8 million funding from UK Research and Innovation (UKRI). The project will be spearheaded by Professor Teresa Lambe, Professor of Vaccinology and Immunology and Calleva Head of Vaccine Immunology in the Department of Paediatrics and Professor Paul Klenerman, Sidney Truelove Professor of Gastroenterology and Director of the Translational Gastroenterology Unit at NDM, both of whom are Principal Investigators at NDM’s Pandemic Sciences Institute.

Similar stories

Immune response may be harnessed to control HIV

Researchers have unveiled primary trial results that show encouraging advances in HIV treatment driven by immune-based therapies. New antibody therapies could offer alternative to current treatments.

Oxford and GSK launch £50m programme to advance cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Fitness compensation in m.tuberculosis: a game of genetic chess

Viktoria Brunner takes us behind the scenes of their latest publication 'Compensatory mutations are associated with increased in vitro growth in resistant clinical samples of Mycobacterium tuberculosis' published in Microbial Genomics.

Emerging Leaders Prize recognises future leaders in hepatitis research

Three outstanding hepatitis researchers have been announced today as winners of the Medical Research Foundation’s seventh Emerging Leaders Prize.

A global collaboration to develop next-generation COVID-19 and flu vaccines

Today Oxford University has launched a new global collaboration backed by £8 million funding from UK Research and Innovation (UKRI). The project will be spearheaded by Professor Teresa Lambe, Professor of Vaccinology and Immunology and Calleva Head of Vaccine Immunology in the Department of Paediatrics and Professor Paul Klenerman, Sidney Truelove Professor of Gastroenterology and Director of the Translational Gastroenterology Unit at NDM, both of whom are Principal Investigators at NDM’s Pandemic Sciences Institute.